Medvantx
Pharmaceutical ManufacturingCalifornia, United States51-200 Employees
Connecting patients, providers, and healthcare organizations to improve lives through service and technology.
Leadership Transition The recent appointment of a new CEO and the departure of the chief commercial officer indicate a potential opening for strategic partnerships and innovative collaborations as the company may be seeking fresh growth initiatives.
Acquisition Growth The acquisition of RxS and integration of its multichannel sample management solutions suggest Medvantx's active expansion strategy, presenting opportunities to offer complementary pharmacy and sample management services.
Technological Innovation The launch of the Medvantx INSIGHTS platform and its focus on mobile and cloud solutions highlight their commitment to digital transformation, creating opportunities to position advanced tech integrations and data analytics solutions.
Industry Recognition Receiving the Innovators of the Year award demonstrates Medvantx's innovation leadership, making it a valuable partner for technology providers aiming to enhance pharma services or supply chain efficiencies.
Market Positioning With a revenue range of 100-250 million and a sizable employee base, Medvantx is well-positioned as a mid-market player, offering numerous opportunities to engage with pharmaceutical manufacturers and healthcare organizations seeking scalable pharmacy services.
Medvantx uses 8 technology products and services including Power BI, RSS, Azure SQL, and more. Explore Medvantx's tech stack below.
| Medvantx Email Formats | Percentage |
| First.Last@medvantx.com | 77% |
| Last@medvantx.com | 21% |
| First@medvantx.com | 1% |
| Last.First@medvantx.com | 1% |
Pharmaceutical ManufacturingCalifornia, United States51-200 Employees
Connecting patients, providers, and healthcare organizations to improve lives through service and technology.
Medvantx's revenue is estimated to be in the range of $100M$250M
Medvantx's revenue is estimated to be in the range of $100M$250M